Bendamustine

 

First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom
fludarabine combination chemotherapy is not appropriate.
Indolent non-Hodgkin’s lymphomas as monotherapy in patients who have progressed during or within
6 months following treatment with rituximab or a rituximab containing regimen.
Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in
combination with prednisone for patients older than 65 years who are not eligible for autologous stem
cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of
thalidomide or bortezomib containing treatmentFirst-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom

 

First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.

Indolent non-Hodgkin’s lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.

Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.

 

 

 

View the SPC...

Download the Bendamustine SPC. You will need Adobe Reader to view this document.

Get "spc-bendamustine-2.5mgml-12_2016.pdf"...

Download